FDA extends approval of Merck’s Keytruda in head and neck cancer

This article was originally published here

The regulator has approved Keytruda as monotherapy and also in combination with a commonly used chemotherapy regimen – platinum and fluorouracil (FU). The approval is for first-line treatment

The post FDA extends approval of Merck’s Keytruda in head and neck cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply